Skepticism Greets Rare Disease Drug Maker CANbridge in Hong Kong IPO
Company’s shares tumble 27% in trading debut a week ago, but have stabilized since then on hopes for strong growth of China’s market for drugs to treat rare diseases Key…
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Innogen Pharma jostles for a slice of the weight-loss market
